Login
Companies $VSTM
$7.73 +$0.03 (0.39%) After hours
Verastem, Inc. logo

Verastem, Inc.

verastem.com

What Do They Do?

Sells a prescription drug combination for adults with recurrent KRAS-mutated low-grade serous ovarian cancer and develops cancer medicines for ovarian, pancreatic, lung and colorectal cancers.

How Do They Make Money?

FY2025 revenue

Who Are Their Customers?

Specialty pharmacies dispense the combination directly to patients, while specialty distributors resell it to healthcare entities that then resell it to patients.

Do Revenues Turn Into Profits?

No. It lost $209.5M in FY2025.

Operating income, FY2025
−550% of revenue
▼ −48% (Loss) vs FY2024 (−$115M, −1150%)
Net income, FY2025
−678% of revenue
▼ −60% (Loss) vs FY2024 (−$130.6M, −1306%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Revenue
▲ +114%
vs $11.2M in Q3 FY2025
Net income
▲ +24% (Loss)
vs −$98.5M in Q3 FY2025
  • Aug 7, 2026 Verastem amended its financing agreement to add revenue-linked notes The new notes may total up to $75.0 million, with quarterly payments tied to product sales.
  • Jun 23, 2026 Verastem announced a planned combination study with Erasca The companies intend to evaluate VS-7375 with Erasca’s investigational drug in preclinical models and may explore a future clinical trial.

Growing. Revenue grew 15.1x in 4 years, from $2.1M in FY2021 to $30.9M in FY2025, about 97% a year.

Commercial product and customer sales The earlier report described the company as developing cancer drug candidates, with no marketed product discussed. The latest report says it markets an approved drug combination in the United States.

Broader drug pipeline The earlier report focused on avutometinib and defactinib; the latest also describes a direct KRAS inhibitor as a clinical-stage program.

Who Do They Compete With?

Competes with Abbvie, AstraZeneca, Bristol Myers Squibb, Erasca, Genentech, Novartis, Pfizer, Astellas Pharma, Bayer, BeOne, Boehringer Ingelheim, Chugai, D3 Bio, Eli Lilly, GenFleet, Incyte, Jacobio, Jiangsu Hengrui Pharmaceuticals, Quanta Therapeutics, and Ranok Therapeutics

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support